

Pablo L Ortiz-Romero

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8610613/publications.pdf>

Version: 2024-02-01

124
papers

6,397
citations

134610

34
h-index

78623

77
g-index

129
all docs

129
docs citations

129
times ranked

9102
citing authors

#	ARTICLE	IF	CITATIONS
1	Post hoc Analysis of a Randomized, Controlled, Phase 2 Study to Assess Response Rates with Chloroquine/Mechlorethamine Gel in Patients with Stage IA–IIA Mycosis Fungoides. <i>Dermatology</i> , 2022, 238, 347-357.	0.9	9
2	Primary cutaneous anaplastic large-cell lymphoma successfully treated with intralesional brentuximab vedotin: a case report. <i>International Journal of Dermatology</i> , 2022, 61, .	0.5	2
3	Single-centre experience of using pegylated liposomal doxorubicin as maintenance treatment in mycosis fungoides. <i>British Journal of Dermatology</i> , 2022, 186, 363-365.	1.4	5
4	Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. <i>Blood</i> , 2022, 140, 419-437.	0.6	58
5	Two cases of generalized eruptive lentiginosis in cutaneous T-cell lymphoma following mogamulizumab treatment. <i>International Journal of Dermatology</i> , 2022, 61, .	0.5	1
6	Drug reaction with eosinophilia and systemic symptoms in a 10-year-old boy sparing lichen planus lesions: an example of reverse isotopic response. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	1
7	Contemporary Treatment Patterns and Response in Relapsed/Refractory Cutaneous T-Cell Lymphoma (CTCL) across Five European Countries. <i>Cancers</i> , 2022, 14, 145.	1.7	7
8	Real-life experience of using pegylated liposomal doxorubicin in primary cutaneous T-cell lymphomas. <i>Clinical and Experimental Dermatology</i> , 2022, 47, 1712-1715.	0.6	3
9	Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial. <i>Lancet Haematology</i> , 2022, 9, e425-e433.	2.2	5
10	Should we be imaging lymph nodes at initial diagnosis of early-stage mycosis fungoides? Results from the PROspective Cutaneous Lymphoma International Prognostic Index (PROCLIP) international study*. <i>British Journal of Dermatology</i> , 2021, 184, 524-531.	1.4	18
11	The changing therapeutic landscape, burden of disease, and unmet needs in patients with cutaneous T-cell lymphoma. <i>British Journal of Haematology</i> , 2021, 192, 683-696.	1.2	24
12	Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome. <i>British Journal of Dermatology</i> , 2021, 184, 978-981.	1.4	6
13	UVA-Degradable Collagenase Nanocapsules as a Potential Treatment for Fibrotic Diseases. <i>Pharmaceutics</i> , 2021, 13, 499.	2.0	1
14	Dermoscopy and reflectance confocal microscopy features of acquired lymphangiectasias following surgery and radiotherapy of breast cancer. <i>International Journal of Dermatology</i> , 2021, 60, e429-e431.	0.5	1
15	Mycosis Fungoides and Sézary Syndrome: An Integrative Review of the Pathophysiology, Molecular Drivers, and Targeted Therapy. <i>Cancers</i> , 2021, 13, 1931.	1.7	23
16	Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 9500-9500.	0.8	4
17	Romidepsin-induced sterile folliculitis in a patient with Sézary syndrome. <i>International Journal of Dermatology</i> , 2021, .	0.5	1
18	Response to brentuximab vedotin versus physician's choice by CD30 expression and large cell transformation status in patients with mycosis fungoides: An ALCANZA sub-analysis. <i>European Journal of Cancer</i> , 2021, 148, 411-421.	1.3	27

#	ARTICLE	IF	CITATIONS
19	The time for new biomarkers in mycosis fungoides/S�azary syndrome is here. British Journal of Dermatology, 2021, 185, 250-251.	1.4	0
20	Lack of Systemic Absorption of Topical Mechlorethamine Gel in Patients with Mycosis Fungoides Cutaneous T-Cell Lymphoma. Journal of Investigative Dermatology, 2021, 141, 1601-1604.e2.	0.3	22
21	Patients with primary cutaneous lymphoma are at risk for severe COVID�19. Data from the Spanish Primary Cutaneous Lymphoma Registry. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e624-e626.	1.3	8
22	Multicentric EORTC retrospective study shows efficacy of brentuximab vedotin in patients who have mycosis fungoides and S�azary syndrome with variable CD30 positivity*. British Journal of Dermatology, 2021, 185, 1035-1044.	1.4	15
23	Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician�s choice in cutaneous T-cell lymphoma: final data. Blood Advances, 2021, 5, 5098-5106.	2.5	46
24	Primary cutaneous peripheral T�cell lymphoma, not otherwise specified: results of a multicentre European Organization for Research and Treatment of Cancer (EORTC) cutaneous lymphoma taskforce study on the clinico�pathological and prognostic features. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 658-668.	1.3	12
25	Health-related quality of life effect of mogamulizumab by patient blood involvement. European Journal of Cancer, 2021, 156, S65-S66.	1.3	1
26	Live imaging of neolymphangiogenesis identifies acute antimetastatic roles of dsRNA mimics. EMBO Molecular Medicine, 2021, 13, e12924.	3.3	1
27	Advanced�stage mycosis fungoides: role of the signal transducer and activator of transcription 3, nuclear factor�B and nuclear factor of activated T cells pathways. British Journal of Dermatology, 2020, 182, 147-155.	1.4	26
28	Prognostic factors in patients with primary cutaneous anaplastic large cell lymphoma: a multicentric, retrospective analysis of the Spanish Group of Cutaneous Lymphoma. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 762-768.	1.3	10
29	Midkine rewires the melanoma microenvironment toward a tolerogenic and immune-resistant state. Nature Medicine, 2020, 26, 1865-1877.	15.2	62
30	Systemic rituximab for the treatment of the indolent forms of primary cutaneous B-cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry. Journal of the American Academy of Dermatology, 2020, 83, 1535-1538.	0.6	4
31	Millimeter�sized facial papules in a patient receiving chronic hemodialysis. JDDG - Journal of the German Society of Dermatology, 2020, 18, 1515-1517.	0.4	0
32	The broad spectrum of dermatological manifestations in COVID�19: clinical and histopathological features learned from a series of 34 cases. Journal of the European Academy of Dermatology and Venereology, 2020, 34, e574-e576.	1.3	37
33	Patient-reported quality of life in patients with relapsed/refractory cutaneous T-cell lymphoma: Results from the randomised phase III ALCANZA study. European Journal of Cancer, 2020, 133, 120-130.	1.3	21
34	Rapidly�developing alopecic nodules in a young man. International Journal of Dermatology, 2020, 59, 1219-1221.	0.5	0
35	<p>Cost of early-stage mycosis fungoides treatments in Spain</p>. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 91-105.	0.7	0
36	Omalizumab as an alternative therapeutic tool in the treatment of bullous pemphigoid: A case report. Dermatologic Therapy, 2019, 32, e12829.	0.8	18

#	ARTICLE	IF	CITATIONS
37	Use of extracellular vesicles from lymphatic drainage as surrogate markers of melanoma progression and <i>BRAF</i> <i>V600E</i> mutation. <i>Journal of Experimental Medicine</i> , 2019, 216, 1061-1070.	4.2	99
38	TIME TO NEXT TREATMENT IN PATIENTS WITH PREVIOUSLY TREATED CUTANEOUS T-CELL LYMPHOMA (CTCL) RECEIVING MOGAMULIZUMAB OR VORINOSTAT: A POST-HOC ANALYSIS OF THE MAVORIC STUDY. <i>Hematological Oncology</i> , 2019, 37, 285-286.	0.8	3
39	<i>p62/SQSTM1</i> Fuels Melanoma Progression by Opposing mRNA Decay of a Selective Set of Pro-metastatic Factors. <i>Cancer Cell</i> , 2019, 35, 46-63.e10.	7.7	50
40	The Circulating Transcriptome as a Source of Biomarkers for Melanoma. <i>Cancers</i> , 2019, 11, 70.	1.7	34
41	Safety of Mogamulizumab in Mycosis Fungoides and SÅ©zary Syndrome: Final Results from the Phase 3 Mavoric Study. <i>Blood</i> , 2019, 134, 5300-5300.	0.6	3
42	Time to next treatment in patients with previously treated cutaneous T-cell lymphoma (CTCL) receiving mogamulizumab or vorinostat: A MAVORIC post-hoc analysis.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7539-7539.	0.8	4
43	Is cyclosporine a good option for the treatment of subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic syndrome?. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2019, 85, 656.	0.2	3
44	Progression-Free Survival and Overall Survival Among a Patient Cohort of Relapsed/Refractory Mycosis Fungoides in France, Germany, Italy, Spain and the United Kingdom. <i>Blood</i> , 2019, 134, 5879-5879.	0.6	0
45	Ara€ ears: an actual drug€induced reaction or a distinctive manifestation of a neutrophilic dermatosis?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 214-216.	0.4	2
46	Blood classification and blood response criteria in mycosis fungoides and SÅ©zary syndrome using flow cytometry: recommendations from the EORTC cutaneous lymphoma task force. <i>European Journal of Cancer</i> , 2018, 93, 47-56.	1.3	105
47	Ara€Ohren € durch Medikamente ausgel€st oder Manifestation einer neutrophilen Dermatose?. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 213-215.	0.4	2
48	PIK3CA€related overgrowth spectrum: concurrence of multiple anomalies in one patient. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 603-605.	0.4	0
49	Phacomatosis pigmentokeratolica: a case of <i>HRAS</i> mosaicism causing rhabdomyosarcoma. <i>British Journal of Dermatology</i> , 2018, 179, 1163-1167.	1.4	13
50	Aprepitant did not modify global disease activity in cutaneous T-cell lymphomas. <i>British Journal of Dermatology</i> , 2018, 178, 1222-1223.	1.4	2
51	Collagenase nanocapsules: An approach to fibrosis treatment. <i>Acta Biomaterialia</i> , 2018, 74, 430-438.	4.1	27
52	Registro de linfomas cut€neos primarios de la AEDV: primer a±o de funcionamiento. <i>Actas Dermo-sifiliogr€ficas</i> , 2018, 109, 610-616.	0.2	13
53	Linear immunoglobulin A dermatosis mimicking toxic epidermal necrolysis: a case report of etanercept treatment. <i>British Journal of Dermatology</i> , 2018, 178, 786-789.	1.4	10
54	First-line treatment in lymphomatoid papulosis: a retrospective multicentre study. <i>Clinical and Experimental Dermatology</i> , 2018, 43, 137-143.	0.6	26

#	ARTICLE	IF	CITATIONS
55	Aprepitant improves refractory pruritus in primary cutaneous T-cell lymphomas: experience of the Spanish Working Group on Cutaneous Lymphomas. <i>British Journal of Dermatology</i> , 2018, 178, e273-e274.	1.4	16
56	Association of <i>APOA5</i> and <i>APOC3</i> Genetic Polymorphisms With Severity of Hypertriglyceridemia in Patients With Cutaneous T-Cell Lymphoma Treated With Bexarotene. <i>JAMA Dermatology</i> , 2018, 154, 1424.	2.0	8
57	Therapierefraktäre Pityriasis rubra pilaris mit gutem Ansprechen auf Ustekinumab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1022-1025.	0.4	2
58	Refractory pityriasis rubra pilaris with good response after treatment with ustekinumab. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 1022-1025.	0.4	7
59	PIK3CA-assoziertes Überwucherspektrum: gleichzeitiges Auftreten mehrerer Anomalien bei einem Patienten. <i>JDDG - Journal of the German Society of Dermatology</i> , 2018, 16, 603-605.	0.4	0
60	The First Year of the AEVD Primary Cutaneous Lymphoma Registry. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 610-616.	0.2	3
61	Developments in the understanding of blood involvement and stage in mycosis fungoides/Sezary syndrome. <i>European Journal of Cancer</i> , 2018, 101, 278-280.	1.3	10
62	Subcutaneous panniculitis-like T-cell lymphoma: Clinical features, therapeutic approach, and outcome in a case series of 16 patients. <i>Journal of the American Academy of Dermatology</i> , 2018, 79, 892-898.	0.6	55
63	Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 1192-1204.	5.1	398
64	Injection-site reaction to ixekizumab histologically mimicking lupus tumidus: Report of two cases. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2018, 84, 610.	0.2	9
65	<i>Alternaria</i> infectoria skin infection in a renal transplant recipient: an emerging phaeohyphomycosis of occidental countries?. <i>International Journal of Dermatology</i> , 2017, 56, e153-e155.	0.5	6
66	Leonine Facies, Flushing, and Systemic Symptoms. <i>JAMA Dermatology</i> , 2017, 153, 925.	2.0	1
67	Condyloma-like lesions in a young woman: Not always synonym of genital warts. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2017, 213, 142-143.	0.5	0
68	<i>DEK</i> oncogene is overexpressed during melanoma progression. <i>Pigment Cell and Melanoma Research</i> , 2017, 30, 194-202.	1.5	19
69	Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial. <i>Lancet</i> , The, 2017, 390, 555-566.	6.3	444
70	Widespread biphasic amyloidosis related to ipilimumab treatment for metastatic melanoma. <i>International Journal of Dermatology</i> , 2017, 56, e189-e191.	0.5	1
71	European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sezary syndrome " Update 2017. <i>European Journal of Cancer</i> , 2017, 77, 57-74.	1.3	363
72	Registro de linfomas cutáneos primarios de la AEDV. <i>Actas Dermo-sifiligráficas</i> , 2017, 108, 181-183.	0.2	5

#	ARTICLE	IF	CITATIONS
73	Whole-body imaging of lymphovascular niches identifies pre-metastatic roles of midkine. <i>Nature</i> , 2017, 546, 676-680.	13.7	123
74	Shared Oncogenic Pathways Implicated in Both Virus-Positive and UV-Induced Merkel Cell Carcinomas. <i>Journal of Investigative Dermatology</i> , 2017, 137, 197-206.	0.3	78
75	Systems analysis identifies melanoma-enriched pro-oncogenic networks controlled by the RNA binding protein CELF1. <i>Nature Communications</i> , 2017, 8, 2249.	5.8	22
76	The new Cutaneous Lymphoma International Prognostic index (CLIPi) for early mycosis fungoides failed to identify prognostic groups in a cohort of Spanish patients. <i>British Journal of Dermatology</i> , 2016, 175, 794-796.	1.4	12
77	Targeting KIR3DL2 in primary cutaneous anaplastic large cell lymphomas. <i>British Journal of Dermatology</i> , 2016, 175, 246-247.	1.4	1
78	Lineage-specific roles of the cytoplasmic polyadenylation factor CPEB4 in the regulation of melanoma drivers. <i>Nature Communications</i> , 2016, 7, 13418.	5.8	46
79	Phase II multicentre trial of oral quisinostat, a histone deacetylase inhibitor, in patients with previously treated stage IB-IVa mycosis fungoides/Sézary syndrome. <i>British Journal of Dermatology</i> , 2016, 175, 80-88.	1.4	56
80	Intra- and Inter-Tumoral Homogeneity of BRAF V600E Mutations in Melanoma Tumors. <i>Journal of Investigative Dermatology</i> , 2015, 135, 3078-3085.	0.3	46
81	Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model. <i>Journal of Clinical Oncology</i> , 2015, 33, 3766-3773.	0.8	328
82	MicroRNA Expression Profiling and DNA Methylation Signature for Deregulated MicroRNA in Cutaneous T-Cell Lymphoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 1128-1137.	0.3	87
83	Mutated JAK kinases and deregulated STAT activity are potential therapeutic targets in cutaneous T-cell lymphoma. <i>Haematologica</i> , 2015, 100, e450-e453.	1.7	59
84	Individualized strategies to target specific mechanisms of disease in malignant melanoma patients displaying unique mutational signatures. <i>Oncotarget</i> , 2015, 6, 25452-25465.	0.8	3
85	PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases. <i>PLoS ONE</i> , 2014, 9, e112148.	1.1	18
86	RAB7 Controls Melanoma Progression by Exploiting a Lineage-Specific Wiring of the Endolysosomal Pathway. <i>Cancer Cell</i> , 2014, 26, 61-76.	7.7	86
87	Rituximab in the Treatment of Primary Cutaneous B-Cell Lymphoma: A Review. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 438-445.	0.2	8
88	Rituximab en el tratamiento de los linfomas cutáneos B primarios: revisión. <i>Actas Dermo-sifiligráficas</i> , 2014, 105, 438-445.	0.2	11
89	PLCG1 mutations in cutaneous T-cell lymphomas. <i>Blood</i> , 2014, 123, 2034-2043.	0.6	193
90	Systemic Treatment of Primary Cutaneous Lymphomas. , 2014, , 445-460.		0

#	ARTICLE	IF	CITATIONS
91	Primary cutaneous marginal zone B-cell lymphoma: Response to treatment and disease-free survival in a series of 137 patients. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 357-365.	0.6	76
92	MicroRNAs as prognostic markers in indolent primary cutaneous B-cell lymphoma. <i>Modern Pathology</i> , 2013, 26, 171-181.	2.9	19
93	NIK Controls Classical and Alternative NF- κ B Activation and Is Necessary for the Survival of Human T-cell Lymphoma Cells. <i>Clinical Cancer Research</i> , 2013, 19, 2319-2330.	3.2	52
94	Hemophagocytic syndrome as a complication in a patient with S \ddot{a} zary syndrome. <i>International Journal of Dermatology</i> , 2013, 52, 733-734.	0.5	1
95	Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas. <i>Haematologica</i> , 2013, 98, 57-64.	1.7	33
96	TCR- β Expression in Primary Cutaneous T-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2013, 37, 375-384.	2.1	122
97	Intralesional rituximab in the treatment of indolent primary cutaneous B-cell lymphomas: an epidemiological observational multicentre study. The Spanish Working Group on Cutaneous Lymphoma. <i>British Journal of Dermatology</i> , 2012, 167, 174-179.	1.4	64
98	Efficacy and safety of bexarotene combined with psoralen/ultraviolet A light (PUVA) compared to PUVA treatment alone in stage IB-IIa mycosis fungoides (MF): Final results from EORTC cutaneous lymphoma task force (CLTF) phase III clinical trial 21011.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8076-8076.	0.8	1
99	Mutations in PLCG1 Is a Frequent Event in Cutaneous T-Cell Lymphomas. <i>Blood</i> , 2012, 120, 300-300.	0.6	0
100	EORTC, ISCL, and USCLC consensus recommendations for the treatment of primary cutaneous CD30-positive lymphoproliferative disorders: lymphomatoid papulosis and primary cutaneous anaplastic large-cell lymphoma*. <i>Blood</i> , 2011, 118, 4024-4035.	0.6	365
101	Primary Cutaneous CD30+ Anaplastic Large-Cell Lymphomas Show a Heterogeneous Genomic Profile: An Oligonucleotide ArrayCGH Approach. <i>Journal of Investigative Dermatology</i> , 2011, 131, 269-271.	0.3	14
102	Clinical End Points and Response Criteria in Mycosis Fungoides and S \ddot{a} zary Syndrome: A Consensus Statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. <i>Journal of Clinical Oncology</i> , 2011, 29, 2598-2607.	0.8	550
103	PIM Kinases Inhibition, a Rational Strategy in Peripheral T-Cell Lymphomas,. <i>Blood</i> , 2011, 118, 3494-3494.	0.6	0
104	PI3K Inhibition As a Potential Therapeutic Strategy in Peripheral T-Cell Lymphomas,. <i>Blood</i> , 2011, 118, 3493-3493.	0.6	0
105	Oligonucleotide Array-CGH Identifies Genomic Subgroups and Prognostic Markers for Tumor Stage Mycosis Fungoides. <i>Journal of Investigative Dermatology</i> , 2010, 130, 1126-1135.	0.3	71
106	Vorinostat interferes with the signaling transduction pathway of T-cell receptor and synergizes with phosphoinositide-3 kinase inhibitors in cutaneous T-cell lymphoma. <i>Haematologica</i> , 2010, 95, 613-621.	1.7	93
107	The EORTC Cutaneous T-Cell Lymphoma (CTCL) Platform. <i>Blood</i> , 2010, 116, 4896-4896.	0.6	0
108	Lipoatrophy Associated With Interferon Alfa Adjuvant Therapy for Melanoma. <i>Archives of Dermatology</i> , 2009, 145, 98-9.	1.7	7

#	ARTICLE	IF	CITATIONS
109	Targeted Activation of Innate Immunity for Therapeutic Induction of Autophagy and Apoptosis in Melanoma Cells. <i>Cancer Cell</i> , 2009, 16, 103-114.	7.7	163
110	Psoralen plus ultraviolet A interferon- γ treatment resistance in mycosis fungoides: the role of tumour microenvironment, nuclear transcription factor- κ B and T-cell receptor pathways. <i>British Journal of Dermatology</i> , 2009, 160, 92-102.	1.4	22
111	Fotofotorecisis. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 443-444.	0.2	0
112	Photopheresis. <i>Actas Dermo-sifiligráficas</i> , 2009, 100, 443-444.	0.2	0
113	Alpha-1-Antitrypsin Deficiency Panniculitis. <i>Dermatologic Clinics</i> , 2008, 26, 447-451.	1.0	47
114	Subcutaneous panniculitis-like T-cell lymphoma: definition, classification, and prognostic factors: an EORTC Cutaneous Lymphoma Group Study of 83 cases. <i>Blood</i> , 2008, 111, 838-845.	0.6	617
115	Lupus-like reaction to interferon at the injection site: report of five cases. <i>Journal of Cutaneous Pathology</i> , 2007, 34, 18-21.	0.7	58
116	EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome. <i>European Journal of Cancer</i> , 2006, 42, 1014-1030.	1.3	390
117	Posible implicación de las alteraciones moleculares de la vía de TNF en la tumorigénesis de la micosis fungoide. Descripción de un posible chip de diagnóstico molecular en micosis fungoide. <i>Actas Dermo-sifiligráficas</i> , 2004, 95, 86-96.	0.2	2
118	p16INK4a Is Selectively Silenced in the Tumoral Progression of Mycosis Fungoides. <i>Laboratory Investigation</i> , 2002, 82, 123-132.	1.7	47
119	p16INK4a Gene Alterations Are Frequent in Lesions of Mycosis Fungoides. <i>American Journal of Pathology</i> , 2000, 156, 1565-1572.	1.9	94
120	Lupus Like Lesions in a Patient with X-Linked Chronic Granulomatous Disease and Recombinant X Chromosome. <i>Dermatology</i> , 1997, 195, 280-283.	0.9	19
121	Cutaneous macular amyloidosis associated with multiple endocrine neoplasia 2A. <i>Clinical and Experimental Dermatology</i> , 1996, 21, 313-314.	0.6	12
122	Is Mycosis fungoides Associated with HTLV-1?. <i>Vox Sanguinis</i> , 1995, 69, 84-84.	0.7	3
123	Clinicopathologic and immunohistochemical studies on lichen amyloidosis and macular amyloidosis. <i>Archives of Dermatology</i> , 1994, 130, 1559-1560.	1.7	20
124	Lymphomatoid papulosis: a study of 18 cases*. <i>Journal of the European Academy of Dermatology and Venereology</i> , 1992, 1, 205-216.	1.3	4